The Assessment of Prednisone In Remission Trial (TAPIR) - Patient Centric Approach
Conditions: Granulomatosis With Polyangiitis; Wegener Granulomatosis; VasculitisInterventions: Drug: 5 mg prednisone; Drug: 0 mg prednisoneSponsors: University of South Florida; National Institutes of Health (NIH); National Heart, Lung, and Blood Institute (NHLBI); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); Office of Rare Diseases (ORD); National Center for Advancing Translational Science (NCATS); Rare Diseases Clinical Research NetworkRecruiting - verified December 2014
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Arthritis | Cardiology | Heart | Prednisone | Research | Rheumatology | Science | Skin | Wegener's Granulomatosis